This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-15 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
=== Jennifer Bevan === Jennifer “Jenni” Bevan (Amy James-Kelly) is a Labour Party politician who defeats Henry Muck in the 2024 general election and is appointed Minister of State for Industry. At the start of series 4, she introduces an online safety bill tightening age-verification rules for porn aggregators such as Siren, triggering a sharp drop in Siren’s stock and prompting Whitney Halberstram, CFO of Siren's payment processor Tender, to pivot away from pornography and gambling clients. Whitney seeks Bevan’s regulatory support through Yasmin, who invites her to Henry’s 40th birthday party, where Bevan meets Lord Alexander Norton, a newspaper proprietor concerned about legacy media’s declining influence under business minister Lisa Dearn. After Henry becomes Tender’s CEO, Yasmin lobbies Bevan to support Tender’s merger with an Austrian bank and its application for a UK banking license. At a regulatory meeting, the Prime Minister’s chief of staff pressures the Prudential Regulation Authority to approve the deal, citing press positioning Bevan as Labour’s new public face, and Bevan begins advocating for Tender. When Tender’s fraud is exposed, Yasmin attempts to shift blame onto the Labour government by persuading Bevan to confirm that Dearn suppressed an internal memo raising concerns about Tender; Bevan refuses. Yasmin circumvents her and runs the headline regardless, leading to Dearn’s resignation and prompting Bevan to rebuke Yasmin for lying and allowing Henry to take the fall.
=== Biological characteristics === Like other aptamers, L-RNA aptamers are able to bind molecules such as peptides, proteins, and substances of low molecular weight. The affinity of L-RNA aptamers to their target molecules often lies in the pico to nanomolar range and is thus comparable to antibodies. L-RNA aptamers themselves have low antigenicity. In contrast to other aptamers, L-RNA aptamers have high stability in blood serum, since they are less susceptible to be cleaved hydrolytically by enzymes. They are excreted by the kidneys in a short time due to their low molar mass (which is below the renal threshold). L-RNA aptamers modified with a higher molar mass, such as PEGylated L-RNA aptamers, show a prolonged plasma half-life.
Late-20th-century DNA sequencing changed lichen systematics, as it did the rest of biology. By the 1990s gene-specific sequencing (e.g., nuclear ribosomal DNA) was accessible, and lichenologists used it to probe deep relationships and test classical schemes. Initial studies centred on nuclear small-subunit rDNA (nuSSU), a slowly evolving gene found in all fungi. Andrea Gargas and co-workers (1995) compared nuSSU sequences from many fungi, including several lichens. Their data supplied the first clear evidence that lichenization arose independently multiple times. Lichen-forming fungi in the sample occupied at least five separate branches of the fungal tree. Three origins lay in the Basidiomycota—for example Omphalina and Multiclavula (mushroom-forming, algal partners) and Dictyonema (cyanobacterial partner). Two further origins occurred in the Ascomycota: one in the large ascolichen clade now placed in Lecanoromycetes, the other in Arthoniomycetes (e.g., some crustose Arthonia species). The pattern contradicted the view that lichens form a single natural group. Instead, 'lichen' is best seen as a functional category—an ecological strategy adopted by disparate fungal lineages. The study suggested that lichen-forming fungi evolved from saprotrophic or parasitic ancestors, not from a single ancestral lichen; some lineages later lost the symbiosis. In other words, the ability to form a lichen could evolve from a non-lichen state multiple times, and perhaps even be lost (as some primarily lichen-forming groups also include non-lichenized fungi).
== References == Carlsson, J.; Forssell Aronsson, E; Hietala, SO; Stigbrand, T; Tennvall, J; et al. (2003). "Tumour therapy with radionuclides: assessment of progress and problems". Radiotherapy and Oncology. 66 (2): 107–117. doi:10.1016/S0167-8140(02)00374-2. PMID 12648782. "Radioisotopes in Industry". World Nuclear Association. Archived from the original on 27 February 2013. Retrieved 2 May 2008. Martin, James (2006). Physics for Radiation Protection: A Handbook. John Wiley & Sons. p. 130. ISBN 978-3527406111.
AMPK activation is required for an increase in the expression of small heterodimer partner, which in turn inhibited the expression of the hepatic gluconeogenic genes phosphoenolpyruvate carboxykinase and glucose 6-phosphatase. Metformin is frequently used in research along with AICA ribonucleotide as an AMPK agonist. The mechanism by which biguanides increase the activity of AMPK remains uncertain: metformin increases the concentration of cytosolic adenosine monophosphate (AMP) (as opposed to a change in total AMP or total AMP/adenosine triphosphate) which could activate AMPK allosterically at high levels; a newer theory involves binding to PEN-2. Metformin inhibits cyclic AMP production, blocking the action of glucagon, and thereby reducing fasting glucose levels. Metformin also induces a profound shift in the faecal microbial community profile in diabetic mice, and this may contribute to its mode of action possibly through an effect on glucagon-like peptide-1 secretion. In addition to suppressing hepatic glucose production, metformin increases insulin sensitivity, enhances peripheral glucose uptake (by inducing the phosphorylation of GLUT4 enhancer factor), decreases insulin-induced suppression of fatty acid oxidation, and decreases the absorption of glucose from the gastrointestinal tract. Increased peripheral use of glucose may be due to improved insulin binding to insulin receptors. The increase in insulin binding after metformin treatment has also been demonstrated in patients with type 2 diabetes.
Sources: en.wikipedia.org
=== Eliminating Sequences === Eliminate the sequences that are more than r% identical. There are two ways to eliminate the sequences. It can be done either by removing sequences from the block or just by finding similar sequences and replace them by new sequences which could represent the cluster. Elimination is done to remove protein sequences that are more similar than the specified threshold.
Capillary action (sometimes called capillarity, capillary motion, capillary rise, capillary effect, or wicking) is the process of a liquid flowing in a narrow space without the assistance of external forces like gravity. The effect can be seen in the drawing up of liquids between the hairs of a paint brush, in a thin tube such as a straw, in porous materials such as paper and plaster, in some non-porous materials such as clay and liquefied carbon fiber, or in biological cells. It occurs because of intermolecular forces between the liquid and surrounding solid surfaces. If the diameter of the tube is sufficiently small, then the combination of surface tension (which is caused by cohesion within the liquid) and adhesive forces between the liquid and container wall act to propel the liquid.
Alex Browne (born 9 August 1992) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Browne played for the Oakleigh Chargers in the TAC Cup. He was drafted by Essendon with pick 48 in the 2010 national draft and made his debut against Melbourne at the Melbourne Cricket Ground in round 11 of the 2011 AFL season. He was delisted in October 2015. His father, Murray Browne, played for Collingwood and Fitzroy in the 1980s and his mother was a cheerleader for Carlton. Browne, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension. Browne had signed for the Northern Blues in the Victorian Football League for the 2016 season before his suspension ended his 2016 season.
Although it is not acknowledged in Psychological Types, it is likely that Jung's theory of psychological types was influenced by Alfred Binet's distinction between two intellectual attitudes: 'introspection' and 'externospection'.
== Enzyme regulation == NADP-ME expression has been shown to be regulated by abiotic stress factors. For CAM plants, drought conditions cause stoma to largely remain shut to avoid water loss by evapotranspiration, which leads to CO2 starvation. In compensation, closed stoma activates the translation of NADP-ME to reinforce high efficiency of CO2 assimilation during the brief intervals of CO2 intake, allowing for carbon fixation to continue. In addition to regulation at the longer time scale by means of expression control, regulation at the short-time scale can occur through allosteric mechanisms. C4 NADP-ME has been shown to be partially inhibited by its substrate, malate, suggesting two independent binding sites: one at the active site and one at an allosteric site. However, the inhibitory effect exhibits pH-dependence – existent at a pH of 7 but not a pH of 8. The control of enzyme activity due to pH changes align with the hypothesis that NADP-ME is most active while photosynthesis is in progress: Active light reactions leads to a rise in basicity within the chloroplast stroma, the location of NADP-ME, leading to a diminished inhibitory effect of malate on NADP-ME and thereby promoting a more active state. Conversely, slowed light reactions leads to a rise in acidity within the stroma, promoting the inhibition of NADP-ME by malate. Because the high energy products of the light reactions, NADPH and ATP, are required for the Calvin cycle to proceed, a buildup of CO2 without them is not useful, explaining the need for the regulatory mechanism.
Sources: en.wikipedia.org
The legislative election of 1957 was followed by several years of political stability that was accompanied by economic stagnation and curtailment of reforms and reformists. One of the last initiatives of the brief reform era was a nuclear weapons–free zone in Central Europe proposed in 1957 by Adam Rapacki, Poland's foreign minister. Culture in the Polish People's Republic, to varying degrees linked to the intelligentsia's opposition to the authoritarian system, developed to a sophisticated level under Gomułka and his successors. The creative process was often compromised by state censorship, but significant works were created in fields such as literature, theater, cinema and music, among others. Journalism of veiled understanding and varieties of native and Western popular culture were well represented. Uncensored information and works generated by émigré circles were conveyed through a variety of channels. The Paris-based Kultura magazine developed a conceptual framework for dealing with the issues of borders and the neighbors of a future free Poland, but for ordinary Poles Radio Free Europe was of foremost importance.
=== Taxonomy === Rhodiola rosea was first described by Pedanius Dioscorides in De Materia Medica. Many North American plants formerly included in R. rosea are now treated separately as Rhodiola integrifolia and Rhodiola rhodantha.
==== India ==== In India, it is a Narcotics prescription-only (NRx) medication used for anxiety disorders, sometimes in combination with other drugs, i.e. the beta blocker propranolol. United Kingdom In the UK, etizolam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.
=== 30 October === RSF brigadier general and suspected war criminal Al-Fateh Abdullah Idris was arrested by the RSF for filming executions of civilians, having boasted of killing more than 2,000 people.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.